CLINICAL TRIALS PROFILE FOR ROCEPHIN
✉ Email this page to a colleague
All Clinical Trials for ROCEPHIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00035347 ↗ | Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia | Completed | Pfizer | Phase 4 | 2001-01-01 | A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens. |
| NCT00037479 ↗ | Brain Imaging and Retreatment Study of Persistent Lyme Disease | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 1999-12-01 | The purpose of this study is to determine whether patients with persistent memory problems after Lyme disease benefit from an additional longer course of IV antibiotic therapy; to use modern brain imaging technology to determine whether the problem in the central nervous system is primarily one of poor blood flow or one of impaired nerve cell functioning; and to try to identify biological markers prior to treatment that will identify patients who are more or less likely to respond to the study treatment. |
| NCT00538694 ↗ | Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia | Completed | Cubist Pharmaceuticals LLC | Phase 3 | 2000-10-31 | To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae. |
| NCT00540072 ↗ | Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae | Completed | Cubist Pharmaceuticals LLC | Phase 3 | 2001-07-30 | A COMPARASON OF CIDECIN™ (DAPTOMYCIN) TO ROCEPHIN® (CEFTRIAXONE) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE |
| NCT00566111 ↗ | Ceftriaxone in the Management of Bipolar Depression | Terminated | Stanley Medical Research Institute | N/A | 2007-09-01 | We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ROCEPHIN
Condition Name
Clinical Trial Locations for ROCEPHIN
Trials by Country
Clinical Trial Progress for ROCEPHIN
Clinical Trial Phase
Clinical Trial Sponsors for ROCEPHIN
Sponsor Name
